Siddharth Padia, MD, a specialist in vascular and interventional radiology at the University of California, Los Angeles Medical Center, discusses the utility of TheraSphere™ Yttrium-90 (Y-90) Glass Microspheres in patients with hepatocellular carcinoma (HCC).

The development of radioembolization and Y-90 for patients with HCC, through the efforts of multiple centers, countries, and clinical trials such as the TARGET trial (NCT03295006), has yielded positive and consistent findings, according to Padia. Y-90 has proven to be a highly efficacious and well-tolerated therapy, demonstrating promising 2- and 3-year overall survivals, he says. 

Additionally, Y-90 does not prevent patients from receiving downstream treatments such as systemic therapies, including immune checkpoint inhibitors, or TKIs. It can also be used as a solo destination therapy, a bridge or downstage therapy to surgical resection or transplantation, in combination with systemic agents, or as a bridge to systemic therapy, Padia concludes.

Videos

Siddharth Padia, MD, discusses the utility of TheraSphere™ Yttrium-90 Glass Microspheres in patients with hepatocellular carcinoma.



Dr. Padia on the Utility of Y-90 Glass Microspheres in HCC

Siddharth Padia, MD, a specialist in vascular and interventional radiology at the University of California, Los Angeles Medical Center, discusses the data that led to the March 2021 

FDA approval of TheraSphere™ Yttrium-90 (Y-90) Glass Microspheres

 for use in patients with hepatocellular carcinoma (HCC).

This is the first device that is approved for HCC in the United States based on data from the following 3 studies: the phase 2 DOSISPHERES-01 trial (NCT02582034), the LEGACY trial, and the TARGET trial (NCT03295006). Results from the trials demonstrated that the approval of this approach was warranted, according to Padia. The TARGET study, however, specifically identified uniform results across multiple institutions, which helped to alleviate concerns that the device could only be optimally used at certain centers, Padia says. Additionally, all 3 studies demonstrated that with the right experience, results could be translatable from one operator to the next, Padia concludes.

Siddharth Padia, MD, discusses the data that led to the March 2021 FDA approval of TheraSphere™ Yttrium-90 Glass Microspheres for use in patients with hepatocellular carcinoma.

Siddharth Padia, MD

Articles

Dr. Padia on the Utility of Y-90 Glass Microspheres in HCC

Dr. Padia on Data Supporting FDA Approval of Y-90 Glass Microspheres in HCC